Lord Pearson of Rannoch: To ask Her Majesty's Government whether they will invite the NHS and the National Institute for Health and Care Excellence to re-consider their decision not to offer Orkambi to cystic fibrosis sufferers in England and Wales.
Luke Hall: To ask the Secretary of State for Health and Social Care, what recent steps the Government has taken to ensure that (a) negotiations between Vertex Pharmaceuticals and NHS England on access to Orkambi for people with cystic fibrosis proceed without further delay and (b) an agreement is reached between the two parties.
Stephen Hepburn: To ask the Secretary of State for Health and Social Care, with reference to the Adjournment debate of 17 July 2018 on Access to Orkambi, Official Report, columns 377-386, if he will take steps to keep hon. Members updated over the summer recess in the event that any progress is made between Vertex and NHS England on making the drug Orkambi available on the NHS for people with Cystic Fibrosis.
Ivan Lewis: To ask the Secretary of State for Health and Social Care, pursuant to the Adjournment debate of 17 July 2018 on Access to Orkambi, Official Report, cols 377-386, what steps he is taking to (a) facilitate and (b) participate as appropriate in a meeting between the chief executives of NHS England and of Vertex to discuss patient access to lumacaftor-ivacaftor and other medicines for cystic fibrosis.
Ben Bradley: To ask the Secretary of State for Health and Social Care, what recent discussions he has had with (a) Vertex and (b) NHS England on access to Orkambi on the NHS.
Ian Austin: ...just artificial intelligence. The development of other life sciences and new technologies can have a massive effect on improving people’s healthcare, such as the development of treatments like Orkambi for people with cystic fibrosis. Will the Secretary of State make it an important priority to cut through the impasse between NHS England and the manufacturer, Vertex, so that people...
Luke Hall: To ask the Secretary of State for Health and Social Care what plans he has to ensure his Department continues to engage and meet with NHS England and Vertex to discuss access to Orkambi.
Luke Hall: To ask the Secretary of State for Health and Social Care, whether ensuring access to Orkambi for people with cystic fibrosis is a priority for his Department.
Luke Hall: To ask the Secretary of State for Health and Social Care, whether a date has been set for the next meeting between NHS England and Vertex to discuss access to the drug Orkambi.
Luke Hall: To ask the Secretary of State for Health and Social Care, what his Department's policy is on Vertex (a) waiving its confidentiality clause on the negotiations around NHS access to the drug Orkambi and (b) disclosing details of its offer to NHS England.
Jeff Smith: To ask the Secretary of State for Health and Social Care, whether he plans to intervene in negotiations between NHS England and pharmaceutical company Vertex on the provision of Orkambi to Cystic Fibrosis patients on the NHS.
Steve Brine: ...have it. Once more, we have heard hon. Members make compassionate—that is a very good word—pleas urging an immediate resolution in the ongoing discussions between NHS England and Vertex to make Orkambi available on the NHS in England. To the hon. Member for North Down (Lady Hermon), who raised this in an intervention, I say that, absolutely, I will make sure my officials are...
Bill Wiggin: To ask the Secretary of State for Health and Social Care, how many times NHS England has met Vertex to discuss Orkambi; and whether any steps have been taken as a result of those meetings.
Stephen Morgan: ...of 16 May 2018, Official Report, column 276, whether officials of his Department have met with the Prime Minister to discuss negotiations between NHS England and Vertex on the supply of the drug Orkambi.
Anneliese Dodds: To ask the Secretary of State for Health and Social Care, what assessment he has made of whether NICE's guidance on the drug Orkambi supports his Department's approach of ensuring that NICE appropriately funds new, targeted technologies for the treatment of rare diseases.
Anne Marie Morris: To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 23 April 2018 to Question 135633, on Orkambi, whether his Department has also written to NHS England in similar terms to encourage them to treat negotiations with urgency.
Paul Masterton: .... We have an odd approach to cost-effectiveness when looking at medicines in this country that I think we need to reassess. That is not only true for Kuvan—we have seen it when talking about Orkambi and for various other issues. I completely agree with the decision of the NSPKU to apply for Kuvan to be placed in the ultra-orphan stream due to the rareness of the condition and the...
Anas Sarwar: ...as it is not considered cost effective, despite it being recognised as clinically effective. I ask again: what cost life? The other drug referred to in our motion is the life-prolonging cystic fibrosis drug Orkambi. It slows the decline in lung function—the main cause of death in cystic fibrosis—by 42 per cent. Orkambi also cuts the number of infections that require...
..., as a matter of urgency, to bring NHS National Services Scotland, the Scottish Medicines Consortium and the relevant pharmaceutical companies together to deliver access to the life-prolonging medicines, Perjeta and Orkambi, for patients in Scotland who need them; notes the commitment that was made by the Scottish Government in December 2016, following the Review of Access to New Medicines...